Evidence map›Paper›PMID 42703399›Full record

ArticleJournal of gastrointestinal oncology2026

Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash.

Paul Stendahl Dy, Emil Lou

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Paul Stendahl DyMarlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
Emil LouDepartment of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-1607-1386

Funding

University of Minnesota Clinical Center for the Study of Pancreatic DiseaseU01DK126300 · NIDDK · UNIVERSITY OF MINNESOTA · PI GREGORY J BEILMAN, Melena D. Bellin · 2020 to 2026
$3.9M
NIDDK NIH HHS U01 DK126300
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

desensitizationImatinibsevere drug rashtherapeutic drug monitoring (TDM)

Identifiers

PMID42703399
PMCPMC13546546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.